Volume 30, Number 5—May 2024
Dispatch
Protective Efficacy of Lyophilized Vesicular Stomatitis Virus–Based Vaccines in Animal Model
Table 1
Infectious titers of lyophilized vaccines after 90 day storage at different temperatures in study of protective efficacy of lyophilized vesicular stomatitis virus–based vaccines in animal model*
Vaccine |
Lyophilization medium |
|||
---|---|---|---|---|
DMEM |
DMEM + LS |
DMEM + LS +T |
DMEM + LS + T + G |
|
VSV∆G/LASVGPC | ||||
4°C | 6.36 (5.49–7.23) | 0.25 (–0.62 to 1.12) | 1.25 (0.38–2.12) | 0.88 (0.005–1.75) |
21°C | NC | 3.00 (2.06–3.94) | 2.88 (1.94–3.82) | 1.50 (0.56–2.44) |
37°C |
NC |
NC |
NC |
NC |
VSV∆G/EBOVGP | ||||
4°C | 1.57 (0.83–2.31) | 0.43 (–0.32 to 1.17) | 1.13 (0.39–1.87) | 1.55 (0.81–2.29) |
21°C | 4.50 (4.22–4.78) | 2.00 (1.72–2.28) | 6.63 (6.35–6.91) | 6.25 (5.97–6.53) |
37°C | 4.38 (4.20–4.56) | 4.50 (4.32–4.68) | 4.38 (4.20–4.56) | 3.75 (3.57–3.93) |
*Values are no. (95% CI), representing the log10 decreases in infectious titers (median 50% tissue culture infectious dose) for vaccines that were lyophilized in the presence of various stabilizers, stored at the indicated temperatures for 90 days, and then reconstituted. Comparisons are between 1 and 90 days after lyophilization. DMEM, Dulbecco modified Eagle medium; G, gelatin; LS, lactalbumin hydrolysate and sucrose; NC, not calculated; T, trehalose; VSV∆G/EBOVGP, vesicular stomatitis virus expressing Ebola virus glycoprotein; VSV∆G/LASVGPC, vesicular stomatitis virus expressing Lassa virus glycoprotein.